Abstract
Trastuzumab has been clearly demonstrated to improve overall survival for both early and metastatic HER2 positive breast cancer. However, despite the improved clinical outcomes seen with the addition of HER2 targeted therapy to conventional cytotoxic agents, the response rates remain between 30-55% and the majority of patients with advanced breast cancer experience disease progression within 1 year. In this review article, we provide a summary of the key mechanisms of resistance to trastuzumab, including the truncated form of HER2 (p95HER2), compensatory up-regulation of receptor cross-talk, genetic mutations and aberrancies in molecular pathways that allow tumor cells to evade cell cycle regulations. In recent years, treatment options for patients with trastuzumab-resistant disease have been developed and approved, including lapatinib and T-DM1. Ongoing research is evaluating multiple other therapeutic regimens that include novel HER2- targeting agents for the treatment of resistant disease. We will review these newer therapies as well as the scientific rationale behind treatment regimens that have been studied in patients with trastuzumab-resistant HER2 positive breast cancer.
Keywords: Breast cancer, HER2, lapatinib, neratinib, metastatic, T-DM1, trastuzumab resistance.
Current Cancer Therapy Reviews
Title:Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options
Volume: 11 Issue: 4
Author(s): Sangmee Bae and Sara Hurvitz
Affiliation:
Keywords: Breast cancer, HER2, lapatinib, neratinib, metastatic, T-DM1, trastuzumab resistance.
Abstract: Trastuzumab has been clearly demonstrated to improve overall survival for both early and metastatic HER2 positive breast cancer. However, despite the improved clinical outcomes seen with the addition of HER2 targeted therapy to conventional cytotoxic agents, the response rates remain between 30-55% and the majority of patients with advanced breast cancer experience disease progression within 1 year. In this review article, we provide a summary of the key mechanisms of resistance to trastuzumab, including the truncated form of HER2 (p95HER2), compensatory up-regulation of receptor cross-talk, genetic mutations and aberrancies in molecular pathways that allow tumor cells to evade cell cycle regulations. In recent years, treatment options for patients with trastuzumab-resistant disease have been developed and approved, including lapatinib and T-DM1. Ongoing research is evaluating multiple other therapeutic regimens that include novel HER2- targeting agents for the treatment of resistant disease. We will review these newer therapies as well as the scientific rationale behind treatment regimens that have been studied in patients with trastuzumab-resistant HER2 positive breast cancer.
Export Options
About this article
Cite this article as:
Bae Sangmee and Hurvitz Sara, Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151119213606
DOI https://dx.doi.org/10.2174/1573394712666151119213606 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science β-Glucans: Old Molecules with Newly Discovered Immunological Activities
Drug Design Reviews - Online (Discontinued) Selection Criteria for Probiotics and Potential of Cereal Based Food Products as Novel Probiotic-Carriers
Current Nutrition & Food Science Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Agents Targeting Prostate Cancer Bone Metastasis
Anti-Cancer Agents in Medicinal Chemistry Transcriptional Regulation as a Pharmacologic Intervention
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Novel Nitro-Heterocycles Sugar and Indoles Candidates as Lead Structures Targeting HepG2 and A549 Cancer Cell Lines
Current Bioactive Compounds Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) Cytotoxic Constituents from Vietnamese Marine Sponge <i>Haliclona oculata (Linnaeus, 1759)</i>
Letters in Organic Chemistry HER2-targeted Therapeutic Strategies for HER2-positive Metastatic Breast Cancers
Current Cancer Therapy Reviews Aligning Animal Models of Clinical Germinal Matrix Hemorrhage, From Basic Correlation to Therapeutic Approach
Current Drug Targets Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry Combined 3D-QSAR, Pharmacophore and Docking Studies on Benzenesulfonamide Derivatives as Potent 12-Lipoxygenase Inhibitors
Letters in Drug Design & Discovery Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism